Name | Ramatroban |
Synonyms | CS-1350 BAY-U3405 BAY U3405 Ramatroban BAY-U3405 (R)-3-(3-(4-fluorophenylsulfonamido)-3,4-dihydro-1H-carbazol-9(2H)-yl)propanoic acid 3R-[[(4-FLUOROPHENYL)SULFONYL]AMINO]-1,2,3,4-TETRAHYDRO-9H-CARBAZOLE-9-PROPANOIC ACID 3-(1,2,3,4-tetrahydrocarbazol-9-yl)propanoic acid [(4-fluorophenyl)sulfonylamino] ester 3R-[[(4-Fluorophenyl)sulfonyl]amino]-1,2,3,4-tetrahydro-9H-. carbazole-9-propanoic acid (3R)-3-[[(4-Fluorophenyl)sulfonyl]amino]-1,2,3,4-tetrahydro-9H-carbazole-9-propionic acid 3-[(3R)-3-(4-Fluorophenylsulfonylamino)-1,2,3,4-tetrahydro-9H-carbazole-9-yl]propionic acid 3-[(3R)-3-{[(4-fluorophenyl)sulfonyl]amino}-1,2,3,4-tetrahydro-9H-carbazol-9-yl]propanoic acid |
CAS | 116649-85-5 |
InChI | InChI=1/C21H21FN2O4S/c22-14-5-8-16(9-6-14)29(27,28)23-15-7-10-20-18(13-15)17-3-1-2-4-19(17)24(20)12-11-21(25)26/h1-6,8-9,15,23H,7,10-13H2,(H,25,26)/t15-/m1/s1 |
Molecular Formula | C21H21FN2O4S |
Molar Mass | 416.47 |
Density | 1.43±0.1 g/cm3(Predicted) |
Melting Point | 134-135° |
Boling Point | 654.7±65.0 °C(Predicted) |
Specific Rotation(α) | D +70.1° (c = 1.0 in methanol) |
Flash Point | 349.7°C |
Solubility | DMSO: ≥40mg/mL |
Vapor Presure | 4.94E-18mmHg at 25°C |
Appearance | solid |
Color | white |
pKa | 4.60±0.10(Predicted) |
Storage Condition | Sealed in dry,2-8°C |
Refractive Index | 1.664 |
In vitro study | Ramatroban is a potent human thromboxane receptor (hTP) antagonist with an IC 50 of 18 nM in a human TP binding assay. Ramatroban inhibits prostaglandin D 2 receptor DP2 (CRTH2) with an IC 50 of 113 nM in a human DP2 binding assay. Ramatroban also inhibits human CYP isoform CYP2C9 with an IC 50 of 15 μM. Ramatroban is a selective thromboxane-type prostanoid (TP) receptor antagonist. PGD 2 -stimulated human eosinophil migration is shown to be mediated exclusively through activation of CRTH2, and surprisingly, these effects are completely inhibited by Ramatroban. Ramatroban is an antagonist for CRTH2, and inhibits PGD 2 -induced migration of eosinophils via CRTH2 blockade. 3 H-labeled PGD 2 binds to a single site on CRTH2 transfectants with high affinity (K D =6.3 nM, B max =450 pM). Nonlabeled PGD 2 inhibits the binding of 3 H-labeled PGD 2 to CRTH2 transfectants in a concentration-dependent manner with an EC 50 value of 2.7 nM. Ramatroban shows significant inhibitory effects on the binding of 3 H-labeled PGD 2 to CRTH2, albeit with much lower potency (IC 50 =100 nM). Ramatroban also inhibits PGD 2 -induced Ca 2+ mobilization in CRTH2 transfectants to almost the same extent with an IC 50 value of 30 nM. Ramatroban completely inhibits the PGD 2 -induced migration of eosinophils in a concentration-dependent manner with an IC 50 value of 170 nM. |
In vivo study | Ramatroban is an orally bioavailable small molecule antagonist of CRTH2. Systemic administration of Ramatroban (30 mg/kg) in CRTH2 +/+ mice produces the same effects as seen in CRTH2 deficiency. Ramatroban completely blocks LPS-induced decreases in social and object exploratory behavior (p<0.01). In addition, tumor-impaired social interaction and object exploratory behavior in CRTH2 +/+ mice are completely reversed by a single injection of Ramatroban, even when the tumor is enlarged. |
Hazard Symbols | Xi - Irritant |
Risk Codes | 36/37/38 - Irritating to eyes, respiratory system and skin. |
Safety Description | S26 - In case of contact with eyes, rinse immediately with plenty of water and seek medical advice. S36/37/39 - Wear suitable protective clothing, gloves and eye/face protection. S45 - In case of accident or if you feel unwell, seek medical advice immediately (show the label whenever possible.) |
WGK Germany | 1 |
1mg | 5mg | 10mg | |
---|---|---|---|
1 mM | 2.401 ml | 12.006 ml | 24.012 ml |
5 mM | 0.48 ml | 2.401 ml | 4.802 ml |
10 mM | 0.24 ml | 1.201 ml | 2.401 ml |
5 mM | 0.048 ml | 0.24 ml | 0.48 ml |